埃克替尼治疗晚期非小细胞肺癌的疗效及对患者血清相关指标水平的影响

Effects of Icotinib on Treatment of Advanced Non-small Cell Lung Cancer and Serum Levels of Related Indexes

目的:分析埃克替尼对晚期非小细胞肺癌的治疗效果及对血清指标的影响。方法:将86例晚期非小细胞肺癌患者按抽签法分成对照组与观察组,各43例。对照组采用多西他赛治疗,观察组采用埃克替尼治疗。观察并比较两组患者治疗前后血清细胞角蛋白21-1(Cyfre21-1)、鳞状细胞癌抗原(SCCA)、血管内皮生长因子(VEDF)、自然杀伤(NK)细胞、CD4^+、CD8^+、CD4^+/CD8^+,白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)、基质金属蛋白酶-2(MMP-2)及基质金属蛋白酶-9(MMP-9)水平、临床疗效以及安全性。结果:观察组疾病控制率高于对照组,差异具有统计学意义(P<0.05)。治疗后,两组患者血清Cyfre21-1、SCCA、CD8^+、LI-8、TNF-α、MMP-2及MMP-9均低于治疗前,且观察组低于对照组,,差异具有统计学意义(P<0.05);治疗后,两组患者血清VEGF水平均降低,且观察组低于对照组,差异具有统计学意义(P<0.05);治疗后,两组患者血清NK、CD4^+及CD4^+/CD8^+均高于治疗前,且观察组高于对照组,差异具有统计学意义(P<0.05);观察组不良反应发生率低于对照组,差异具有统计学意义(P<0.05)。结论:埃克替尼对晚期非小细胞肺癌的临床效果肯定,可下调血清VEGF表达。

Objective：To analyze the clinical effect of icotinib on treatment of advanced non-small cell lung cancer and serum index levels.Methods：86 patients with advanced non-small cell lung cancer were selected and randomly divided into the control group and the observation group with 43 cases in each group.The patients in the control group were treated with docetaxel,while the patients in the observation group were treated with icotinib.Then the serum levels of cytokeratin 21-1 （Cyfre21-1）,squamous cell carcinoma antigen （SCCA）,natural killer （NK） cells,CD4^＋,CD8^＋,CD4^＋/CD8^＋,intefleukin-8 （IL-8）,tumor necrosis factor-α （TNF-c）,matrix metalloproteinase-2 （MMP-2） and matrix metalloproteinases-9 （MMP-9） of patients and the clinical efficacy and security.Results：The disease control rate of observation group was higher than that of the control group,and the difference was statistically significant （P〈0.05）.After treatment,the serum levels of SCCA,Cyfre21-1,CD8^＋,LI-8,TNF-α,MMP-2 and MMP-9 in the two groups decreased,and the observation group was lower than that of the control group,and the differences were statistically significant （P〈0.05）;After treatment,the serum levels of VEGF in the two groups decreased,and the observation group was lower than that of the control group,and the differences were statistically significant （P〈0.05）;After treatment,the serum levels ofNK,CD4^＋ and CD4^＋/CD8^＋ in the two groups increased,and the observation group was higher than that of the control group,and the differences were statistically significant （P〈0.05）.The adverse reactions of the observation group was lower than that of the control group,and the difference was statistically significant （P〈0.05）.Conclusion：The clinical efficacy oficotinib in the treatment of advanced non-small cell lung cancer can reduce the serum levels of SCCA,Cyfre21-1,CD8^＋,LI-8,TNF-α,MMP-2 and MMP-9 and increase the NK,CD4^＋ and CD4^＋/CD8^＋ of patients.